International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository

Launched by CHILDREN'S HOSPITAL MEDICAL CENTER, CINCINNATI · Mar 30, 2017

Keywords

ClinConnect Summary

The International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository is a clinical trial aimed at understanding more about DIPG and DMG tumors. These are types of brain tumors that can be very challenging to treat. The goal of this study is to collect important information and samples, like tissue from tumors, from patients diagnosed with these conditions. By gathering this information, researchers hope to learn how these tumors behave on a biological level. This will help improve diagnosis and treatment options in the future, as well as enable scientists around the world to collaborate more effectively.

Anyone diagnosed with a DIPG or DMG tumor—whether currently receiving treatment or previously diagnosed—is welcome to participate in this study. Participants, or their guardians if they are minors, will need to provide consent for their information and samples to be used in research. By joining this registry, participants can help contribute to a better understanding of these tumors, which may lead to new treatments and improved care for patients in the future. It's important to note that this study is currently recruiting participants of all ages and genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients of any age (living or deceased) with a diagnosis (either current or past) of a DIPG/DMG tumor
• • Unless the patient is deceased, all patients and/or one parent or legal guardian must provide written informed consent as well as HIPAA/release of information consent.